UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    Aug

    17

    UCB Partners in Health Economics and Outcomes Research to Evolve Solutions for Seizure Clusters

    Read More Share:linkedin| twitter| email

    May

    23

    UCB Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to be Presented at EULAR 2022

    Read More Share:linkedin| twitter| email

    May

    23

    First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022

    Read More Share:linkedin| twitter| email

    May

    10

    UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis

    Read More Share:linkedin| twitter| email

    May

    02

    JAMA Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of FINTEPLA® (fenfluramine) Oral Solution in Lennox-Gastaut Syndrome (LGS)

    Read More Share:linkedin| twitter| email

    Apr

    01

    UCB Showcases Strength of Broad Neurology Portfolio at 74th American Academy of Neurology (AAN) Annual Meeting

    Read More Share:linkedin| twitter| email

    Mar

    28

    FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)

    Read More Share:linkedin| twitter| email

    Mar

    26

    New Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting

    Read More Share:linkedin| twitter| email

    Mar

    07

    UCB Completes Acquisition of Zogenix, Inc.

    Read More Share:linkedin| twitter| email

    Feb

    04

    UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results

    Read More Share:linkedin| twitter| email

    © 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
    USPR-CORP-0115-00003(2)